Friday, May 1, 2026

North Korea’s Yongbyon Nuclear Facility Shows Signs of Plutonium Production

Recent satellite images show steam emissions at North Korea's Yongbyon nuclear site, indicating ongoing plutonium production activities.

“NORMAL” OR A DEADLY LIE? The $30 Billion Question: Is Kim’s Uranium Waste Floating Toward Your Kitchen Sink?

South Korea confirms no abnormalities in monitoring for radioactive wastewater from North Korea's uranium plant, ensuring ongoing surveillance.

Seoul’s Calm-Response Strategy: As Tariffs Loom at 25%, Can Korea Keep the U.S. Deal at 15%?

Yeo Han Ku reassures calm amid Trump's tariff threats, emphasizing South Korea's commitment to trade relations and national interests.

Tag: Zymfentra

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

How Celltrion’s Local Production Strategy Eliminates U.S. Drug Tariffs Influence

Celltrion resolves tariff impacts on U.S. sales, boosting local production and growth opportunities for its biosimilars, including Zymfentra.

How Zymfentra’s Prescription Rates Tripled in January: A Game-Changer for Celltrion

Celltrion's Zymfentra sees a 213% rise in U.S. prescriptions, marking significant growth since its launch, driven by market demand.

Celltrion’s Zymfentra: How This Breakthrough Drug is Driving Record Sales

Celltrion expects record sales driven by Zymfentra's success, expanding into new biosimilars and CDMO business for future growth.

K-Bio Targets the U.S. Market: Celltrion and Samsung Bioepis Close in on Originator Drugs

Celltrion and Samsung Bioepis are expanding in the U.S. market, showing strong growth in biosimilars like Zymfentra and Hadlima.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.